Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.
Garderet L et al. Haematologica. 2016 Sep 9. pii: haematol.2016.150334. [Epub ahead of print].

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
Biran N et al. Blood Cancer J. 2016 Sep 2;6(9):e466. doi: 10.1038/bcj.2016.68.

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
Rasche L et al. Biol Blood Marrow Transplant. 2016 Aug 31. pii: S1083-8791(16)30320-2. doi: 10.1016/j.bbmt.2016.08.024. [Epub ahead of print].

Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.
Winkelmann N et al. J Cancer Res Clin Oncol. 2016 Sep 17. [Epub ahead of print].

Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
Worel N et al. J Clin Apher. 2016 Aug 31. doi: 10.1002/jca.21496. [Epub ahead of print].

A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients withMultiple Myeloma.
Biran N et al. Biol Blood Marrow Transplant. 2016 Aug 31. pii: S1083-8791(16)30292-0. doi: 10.1016/j.bbmt.2016.08.017. [Epub ahead of print].

Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Stewart AK et al. J Clin Oncol. 2016 Sep 6. pii: JCO669648. [Epub ahead of print].

Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma.
Wang C et al. Hematology. 2016 Sep 25:1-5. [Epub ahead of print].

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma.
Wei D et al. Oncotarget. 2016 Sep 21. doi: 10.18632/oncotarget.12162. [Epub ahead of print].

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Nijhof IS et al. Blood. 2016 Sep 19. pii: blood-2016-07-729236. [Epub ahead of print].

A Three-Drug Combo for Multiple Myeloma.
[No authors listed] Cancer Discov. 2016 Sep 14. [Epub ahead of print].

Daratumumab combination prolongs myeloma survival.
Das M. Lancet Oncol. 2016 Sep 2. pii: S1470-2045(16)30439-9. doi: 10.1016/S1470-2045(16)30439-9. [Epub ahead of print].